Novo's oral amycretin could lead to more weight loss beyond 12 weeks, according to early-stage trial
Novo Nordisk touted more data for its oral amycretin, noting that subjects had not reached a plateau in their weight loss at the end of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
